CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 1)

EP: 1.Treatment Approaches in Multiple Myeloma

EP: 2.FDA Approvals for Multiple Myeloma

EP: 3.CARTITUDE-1 Baseline Demographics

EP: 4.An Overview of CARTITUDE-1

EP: 5.CARTITUDE-1 Patients

EP: 6.CARTITUDE-1 Efficacy Findings

EP: 7.CARTITUDE-1 Safety Overview

EP: 8.CARTITUDE-1 Primary Findings Discussion

Now Viewing

EP: 9.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 1)

EP: 10.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 2)

Further analysis highlighted that 12 patients maintained minimal residual disease–negative complete remission for more than 5 years without maintenance therapy. These “one-and-done” responses represent a new standard for defining potential cure in myeloma.

This finding redefines expectations in multiple myeloma, where continuous therapy has long been the norm. The absence of relapse in these patients supports the possibility of true functional cures using chimeric antigen receptor T-cell therapy.

Ongoing randomized trials, such as CARTITUDE-5 and CARTITUDE-6, aim to evaluate ciltacabtagene autoleucel in frontline settings and as a potential alternative to autologous stem cell transplant, further advancing the goal of curative therapy.